Related references
Note: Only part of the references are listed.Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
S. M. Matulis et al.
LEUKEMIA (2016)
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor
Ahmed Hamed Salem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study
Suresh K. Agarwal et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
Stephan Stilgenbauer et al.
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4Wild-type and CXCR4WHIM mutated Waldenstrom macroglobulinaemia cells
Yang Cao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
Fabiola Cervantes-Gomez et al.
CLINICAL CANCER RESEARCH (2015)
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
L. Li et al.
LEUKEMIA (2015)
Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
D. C. Phillips et al.
BLOOD CANCER JOURNAL (2015)
New dimension in therapeutic targeting of BCL-2 family proteins
Samaher Besbes et al.
ONCOTARGET (2015)
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
Xiaoxian Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
Scott Ackler et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Sofie Peirs et al.
BLOOD (2014)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
C. Touzeau et al.
LEUKEMIA (2014)
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Triona Ni Chonghaile et al.
CANCER DISCOVERY (2014)
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors
Tun Kiat Ko et al.
ONCOTARGET (2014)
ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Cassandra J. Vandenberg et al.
BLOOD (2013)
ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets
Meike Vogler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Share Paper
